Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 571 to 585 of 735 results for adult social

  1. Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)

    Evidence-based recommendations on bempedoic acid with ezetimibe (Nilemdo and Nustendi) for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults.

  2. Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing aids reduce the incidence of dementia?

    NG98/3 Question Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing aids reduce the...

  3. Supporting people to plan for the future: What is the effectiveness and cost-effectiveness of early, preventative support for people with complex needs?

    Source guidance details Comes from guidance Social work with adults experiencing complex needs Number NG216 Date issued

  4. Decision-making:- What interventions, systems and processes are effective and cost effective in changing health and social care practitioners' decision-making and ensuring appropriate antimicrobial stewardship?

    systems and processes are effective and cost effective in changing health and social care practitioners' decision-making and ensuring...

  5. Ways of providing advocacy services: What is the effectiveness and acceptability of providing advocacy through different approaches?

    details Comes from guidance Advocacy services for adults with health and social care needs Number NG227 Date issued November

  6. Dupilumab for treating moderate to severe atopic dermatitis (TA534)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.

  7. Brodalumab for treating moderate to severe plaque psoriasis (TA511)

    Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.

  8. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

  9. Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)

    Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.

  10. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)

    Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.

  11. Individual circumstances and the risk of dependence: Do individual circumstances such as social distress, low income or limited access to alternative sources of support lead to an increased risk of problems associated with dependence on prescribed medicines?

    circumstances and the risk of dependence: Do individual circumstances such as social distress, low income or limited access to...

  12. Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)

    Evidence-based recommendations on berotralstat (Orladeyo) for preventing recurrent attacks of hereditary angioedema in people 12 years and older.

  13. What is the clinical and cost effectiveness of cognitive rehabilitation for people with Multiple sclerosis (MS)?

    activities. People with MS who have cognitive problems often engage in fewer social and vocational activities, are less likely to be in...

  14. Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA736)

    Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.